MoonLake Immunotherapeutics has kicked off a year of readouts for its much-hyped inflammatory disease prospect with a mid-stage win in a type of arthritis.
- Home |
- MoonLake’s phase 2 arthritis win kicks off pivotal year for IL-17 nanobody
MoonLake’s phase 2 arthritis win kicks off pivotal year for IL-17 nanobody
- February 23, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
